Cite
Merchant M, Moffat J, Schaefer G, et al. Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. PLoS One. 2018;13(1):e0192059doi: 10.1371/journal.pone.0192059.
Merchant, M., Moffat, J., Schaefer, G., Chan, J., Wang, X., Orr, C., Cheng, J., Hunsaker, T., Shao, L., Wang, S. J., Wagle, M. C., Lin, E., Haverty, P. M., Shahidi-Latham, S., Ngu, H., Solon, M., Eastham-Anderson, J., Koeppen, H., Huang, S. A., Schwarz, J., Belvin, M., Kirouac, D., & Junttila, M. R. (2018). Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. PloS one, 13(1), e0192059. https://doi.org/10.1371/journal.pone.0192059
Merchant, Mark, et al. "Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors." PloS one vol. 13,1 (2018): e0192059. doi: https://doi.org/10.1371/journal.pone.0192059
Merchant M, Moffat J, Schaefer G, Chan J, Wang X, Orr C, Cheng J, Hunsaker T, Shao L, Wang SJ, Wagle MC, Lin E, Haverty PM, Shahidi-Latham S, Ngu H, Solon M, Eastham-Anderson J, Koeppen H, Huang SA, Schwarz J, Belvin M, Kirouac D, Junttila MR. Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. PLoS One. 2018 Jan 25;13(1):e0192059. doi: 10.1371/journal.pone.0192059. eCollection 2018. PMID: 29370292; PMCID: PMC5785022.
Copy
Download .nbib
